EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy

Study limitation reported by the research below: “Long-term data on reduction of hard liver endpoints (cirrhosis, liver cancer, transplantation) for both agents are still awaited from ongoing studies, so benefit-risk estimates may change.”